Ophthalmic compounding, intravitreal injections and topical eye drops prepared by a pharmacy rather than a manufacturer, sits under some of the closest sterility scrutiny in compounding practice. A compounded eye drop or intravitreal injection is applied past the eye's own natural defenses, so a contamination failure that would be minor elsewhere can cause endophthalmitis and permanent vision loss. The Food and Drug Administration has escalated inspections and warning letters against compounding pharmacies that prepare ophthalmic sterile preparations, citing insanitary conditions, subpotent product, and release of drug before sterility testing is complete. For a compounding pharmacy, one failed sterility result on an eye drop or injection can trigger a warning letter, a product recall, a state board suspension, and referral for civil or criminal review.
The Outbreak History Behind the Scrutiny
The regulatory attention traces to documented outbreaks tied to compounded ophthalmic injections, not to an overcautious rule written in the abstract. Between February and March 2013, five patients in Georgia and Indiana developed endophthalmitis after receiving intravitreal bevacizumab that a compounding pharmacy had repackaged from single-use manufacturer vials into individual syringes, under conditions the Centers for Disease Control and Prevention found did not conform to USP <797> standards for sterile preparations. The Georgia Drugs and Narcotics Agency suspended the pharmacy's sterile compounding operations once the source was traced. That same pharmacy had already distributed the repackaged product to eleven clinics in four states, which is the pattern regulators now watch for: a single sterility lapse in a repackaging or compounding pharmacy reaching patients across state lines before it is caught.
Sterility Standards Under USP 797
USP General Chapter <797> sets the sterile compounding standard inspectors apply to ophthalmic preparations, covering personnel training, environmental monitoring, and the beyond-use date assigned to a finished product. A multi-dose, non-preserved ophthalmic solution compounded for a single patient is treated as a Category 2 preparation under the chapter, limited to a 24-hour beyond-use date at room temperature or 72 hours under refrigeration unless sterility testing supports a longer date. Compounding outside a certified primary engineering control, or repackaging a manufacturer's single-use vial across multiple patients without validated controls, is the exact fact pattern regulators have cited in past ophthalmic sterility failures. A 503A or 503B registration changes which cGMP obligations attach to the pharmacy, not the underlying sterility standard the finished eye product has to meet.
FDA's Warning Letter to Boothwyn Pharmacy
The pattern surfaced again in a warning letter FDA issued to Boothwyn Pharmacy, LLC on January 16, 2026. FDA investigators found the pharmacy's Fluorescein 2% Ophthalmic Solution tested at 85.9% and 76.1% of its labeled strength, rendering it both subpotent and misbranded, and found that drug products intended to be sterile were prepared and held under insanitary conditions. The letter also flagged the pharmacy's practice of releasing sterile drug products, without limiting the practice to ophthalmic preparations, before receiving final sterility test results, and cited sterility and potency failures between July 2024 and May 2025 where patients were not notified. A warning letter is a formal finding, not a settlement, and it starts a compliance clock: the pharmacy must correct the violations on FDA's timeline or face seizure, injunction, or referral for further enforcement.
The eye has no barrier to stop a contaminated compound once it is instilled or injected, which is why a single sterility failure in ophthalmic compounding can cost a patient their vision and a pharmacy its license.
Why Early Legal Counsel Is Critical
It is critical that compounding pharmacies promptly retain experienced healthcare defense counsel upon receiving an FDA Form 483, a warning letter, a state board inspection notice, or any other government inquiry into ophthalmic sterile compounding. Early legal intervention can protect the pharmacy's rights, ensure appropriate responses to FDA and state board requests, avoid inadvertent admissions, preserve relevant defenses, and allow counsel to communicate with investigators on the pharmacy's behalf. Delaying legal representation can significantly affect the outcome of a matter and expose the pharmacy to unnecessary risk.
How Health Law Alliance Can Help
Health Law Alliance defends compounding pharmacies against FDA warning letters, state board inspections, and sterility-related enforcement actions involving ophthalmic and other sterile preparations. Our attorneys work with pharmacies on 503A and 503B compliance and on USP 797 and 800 inspection response after a Form 483 or warning letter. If your pharmacy compounds ophthalmic preparations and has received an FDA inquiry or state board notice, contact us for a free, confidential consultation.
